Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide

Abhishek Jha; Mayank Patel; Eva Baker; Melissa K. Gonzales; Alexander Ling; Corina Millo; Marianne Knue; Ali Cahid Civelek; Karel Pacak

doi:10.1007/s13139-019-00629-3

Role of ⁶⁸Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide

Abhishek Jha, Mayank Patel, Eva Baker, Melissa K. Gonzales, Alexander Ling, Corina Millo, Marianne Knue, Ali Cahid Civelek, Karel Pacak

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

We describe an unusual case of a 42-year-old female with an unresectable succinate dehydrogenase subunit B (SDHB)-related pterygopalatine fossa paraganglioma. She underwent somatostatin receptor imaging with ⁶⁸Ga-DOTA(0)-Tyr(3)-octreotate (⁶⁸Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT), which showed uptake in the above mentioned tumor. Hence, the patient was started on octreotide, a cold somatostatin analog, and responded with tumor stabilization and improvement of clinical symptoms for 36 months since initiation of octreotide therapy. This case demonstrates the role of ⁶⁸Ga-DOTATATE PET/CT in diagnostic localization and its subsequent role in treatment using cold somatostatin analog as a potential choice of therapy in the management of paraganglioma in an unusual location with limited therapeutic options.

Original language	English (US)
Pages (from-to)	48-52
Number of pages	5
Journal	Nuclear Medicine and Molecular Imaging
Volume	54
Issue number	1
DOIs	https://doi.org/10.1007/s13139-019-00629-3
State	Published - Feb 1 2020

Keywords

Ga-DOTATATE PET/CT
Lu-DOTATATE
Octreotide
PRRT
Paraganglioma
SDHB
SSTR
Somatostatin analog

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s13139-019-00629-3

Cite this

@article{9fc5b75240e84ffabe45f2ec71314832,

title = "Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide",

abstract = "We describe an unusual case of a 42-year-old female with an unresectable succinate dehydrogenase subunit B (SDHB)-related pterygopalatine fossa paraganglioma. She underwent somatostatin receptor imaging with 68Ga-DOTA(0)-Tyr(3)-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT), which showed uptake in the above mentioned tumor. Hence, the patient was started on octreotide, a cold somatostatin analog, and responded with tumor stabilization and improvement of clinical symptoms for 36 months since initiation of octreotide therapy. This case demonstrates the role of 68Ga-DOTATATE PET/CT in diagnostic localization and its subsequent role in treatment using cold somatostatin analog as a potential choice of therapy in the management of paraganglioma in an unusual location with limited therapeutic options.",

keywords = "Ga-DOTATATE PET/CT, Lu-DOTATATE, Octreotide, PRRT, Paraganglioma, SDHB, SSTR, Somatostatin analog",

author = "Abhishek Jha and Mayank Patel and Eva Baker and Gonzales, {Melissa K.} and Alexander Ling and Corina Millo and Marianne Knue and Civelek, {Ali Cahid} and Karel Pacak",

note = "Funding Information: This study was funded by the National Institutes of Health (grant number Z1AHD008735 ) awarded to Karel Pacak. This work was supported, in part, by the Intramural Research Program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development and was supported, in part, by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute. Acknowledgments Publisher Copyright: {\textcopyright} 2020, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.",

year = "2020",

month = feb,

day = "1",

doi = "10.1007/s13139-019-00629-3",

language = "English (US)",

volume = "54",

pages = "48--52",

journal = "Nuclear Medicine and Molecular Imaging",

issn = "1869-3474",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide

AU - Jha, Abhishek

AU - Patel, Mayank

AU - Baker, Eva

AU - Gonzales, Melissa K.

AU - Ling, Alexander

AU - Millo, Corina

AU - Knue, Marianne

AU - Civelek, Ali Cahid

AU - Pacak, Karel

N1 - Funding Information: This study was funded by the National Institutes of Health (grant number Z1AHD008735 ) awarded to Karel Pacak. This work was supported, in part, by the Intramural Research Program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development and was supported, in part, by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute. Acknowledgments Publisher Copyright: © 2020, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - We describe an unusual case of a 42-year-old female with an unresectable succinate dehydrogenase subunit B (SDHB)-related pterygopalatine fossa paraganglioma. She underwent somatostatin receptor imaging with 68Ga-DOTA(0)-Tyr(3)-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT), which showed uptake in the above mentioned tumor. Hence, the patient was started on octreotide, a cold somatostatin analog, and responded with tumor stabilization and improvement of clinical symptoms for 36 months since initiation of octreotide therapy. This case demonstrates the role of 68Ga-DOTATATE PET/CT in diagnostic localization and its subsequent role in treatment using cold somatostatin analog as a potential choice of therapy in the management of paraganglioma in an unusual location with limited therapeutic options.

AB - We describe an unusual case of a 42-year-old female with an unresectable succinate dehydrogenase subunit B (SDHB)-related pterygopalatine fossa paraganglioma. She underwent somatostatin receptor imaging with 68Ga-DOTA(0)-Tyr(3)-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT), which showed uptake in the above mentioned tumor. Hence, the patient was started on octreotide, a cold somatostatin analog, and responded with tumor stabilization and improvement of clinical symptoms for 36 months since initiation of octreotide therapy. This case demonstrates the role of 68Ga-DOTATATE PET/CT in diagnostic localization and its subsequent role in treatment using cold somatostatin analog as a potential choice of therapy in the management of paraganglioma in an unusual location with limited therapeutic options.

KW - Ga-DOTATATE PET/CT

KW - Lu-DOTATATE

KW - Octreotide

KW - PRRT

KW - Paraganglioma

KW - SDHB

KW - SSTR

KW - Somatostatin analog

UR - http://www.scopus.com/inward/record.url?scp=85078359103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078359103&partnerID=8YFLogxK

U2 - 10.1007/s13139-019-00629-3

DO - 10.1007/s13139-019-00629-3

M3 - Article

C2 - 32206131

AN - SCOPUS:85078359103

SN - 1869-3474

VL - 54

SP - 48

EP - 52

JO - Nuclear Medicine and Molecular Imaging

JF - Nuclear Medicine and Molecular Imaging

IS - 1

ER -